MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

Core Insights - MAIA Biotechnology, Inc. presented significant findings regarding ateganosine at the ESMO Congress 2025, highlighting its potential in treating non-small cell lung cancer (NSCLC) with limited treatment options [1][2] Group 1: Clinical Trial Highlights - The e-posters showcased at ESMO indicated exceptional extended survival rates in third-line NSCLC patients, with one patient surviving 30 months after starting therapy in March 2023 [2] - The THIO-101 Phase 2 clinical trial is designed to evaluate the anti-tumor activity of ateganosine followed by PD-(L)1 inhibitors, focusing on patients who have shown resistance to previous treatments [5] - The trial aims to assess both the safety and tolerability of ateganosine and its clinical efficacy using Overall Response Rate (ORR) as the primary endpoint [5] Group 2: About Ateganosine - Ateganosine is a first-in-class investigational telomere-targeting agent currently in clinical development for NSCLC, aiming to induce selective cancer cell death and activate immune responses [4] - The drug works by modifying telomeric DNA and has shown promise in inducing tumor regression in advanced cancer models when combined with PD-(L)1 inhibitors [4] Group 3: Company Overview - MAIA Biotechnology focuses on developing targeted immunotherapies for cancer, with ateganosine being a key component of its pipeline aimed at improving treatment outcomes for patients with telomerase-positive cancer cells [7]